Johnson & Johnson (NYSE: JNJ) recently reported its Q3 results, with revenues and earnings exceeding our estimates.
Johnson & Johnson reported better-than-expected third-quarter sales and raised its full-year revenue guidance.
Johnson & Johnson's Q3 2024 results surpassed analyst expectations, reporting $2.42 EPS and $22.47 billion in sales. Updated ...
Though psoriasis affects people of all skin tones, that diversity isn’t always represented in portrayals of the condition in ...
Baker High School principal John Poiroux told AL.com in February that he interviewed 19 different candidates to find the next ...
Third-quarter results exceeded estimates, but the company also lowered overall earnings expectations for 2024.
Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...
History will be in the air in New Orleans on Thursday night as the Saints honor Drew Brees during their game against the ...
The innovative medicine and medtech segments showed solid sales growth. Johnson & Johnson reported a strong increase in sales, but earnings fell due to one-time charges. In the wake of last year's ...
Naturally, much of the near 10-minute discussion was focused on the defense and its struggles. Just one year after leading ...
5hon MSN
A Springfield resident and local real estate entrepreneur, Evan Plotkin has just been awarded $15 million after a jury found ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback